Erythropoietin Administration May Potentiate Mobilization of Storage Iron in Patients on Oral Iron Chelation Therapy
- 1 January 2006
- journal article
- clinical trial
- Published by Taylor & Francis in Hemoglobin
- Vol. 30 (1) , 105-112
Abstract
Five, repeatedly transfused, patients with refractory anemia (RA) or RA with ringed sideroblast (RARS) subtypes of myelodysplastic syndrome (MDS), with serum ferritin (SF) levels of >2,000 μg/L, and one female with Hb E [β26(B8)Glu→Lys]/β0-thalassemia (thal) with an SF level of 1,760 μg/L, were treated with deferiprone (L1) at the dose of 4–6 g per day for at least 26 months. Beginning in the second month, all patients received recombinant human erythropoietin (rHuEPO) at the dose of 150 IU/kg thrice weekly, subcutaneously for 24 months. A significant increase in iron excretion after combined administration of L1 and rHuEPO compared to treatment with L1 as a single agent, was observed in all patients. The amount of excreted iron in urine ranged from 7.5 to almost 20 mg per day. In one patient, a response to rHuEPO resulted in transfusion independence and her SF decreased from 2086 to 879 μg/L. In four MDS patients, who remained dependent on red blood cell (RBC) transfusions, simultaneous administration of L1 and rHuEPO enabled the stabilization of SF levels, despite continuing iron load from the transfusions. Combined administration of rHuEPO and oral iron chelators may potentiate mobilization of storage iron and maintain iron balance in transfusion-dependent iron overloaded early MDS patients.Keywords
This publication has 15 references indexed in Scilit:
- Hepcidin—a regulator of intestinal iron absorption and iron recycling by macrophagesBest Practice & Research Clinical Haematology, 2005
- Iron requirements in erythropoietin therapyBest Practice & Research Clinical Haematology, 2005
- Myelodysplastic Syndromes — Coping with Ineffective HematopoiesisNew England Journal of Medicine, 2005
- The Design and Development of Deferiprone (L1) and Other Iron Chelators for Clinical Use: Targeting Methods and Application ProspectsCurrent Medicinal Chemistry, 2004
- A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of lifeBritish Journal of Haematology, 2003
- Guidelines for the diagnosis and therapy of adult myelodysplastic syndromesBritish Journal of Haematology, 2003
- Best supportive care for the anaemia of myelodysplasia: inclusion of recombinant erythropoietin therapy?Leukemia Research, 2001
- The myelodysplastic syndromes in 1996: Complex stem cell disorders confounded by dual actions of cytokinesLeukemia Research, 1996
- Long‐term trial with the oral iron chelator 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one (L1) I. IRON CHELATION AND METABOLIC STUDIESBritish Journal of Haematology, 1990
- Proposals for the classification of the myelodysplastic syndromesBritish Journal of Haematology, 1982